Compare iShares TIPS Bond ETF (TIP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares TIPS Bond ETF vs TransMedics Group Inc — how do they compare? iShares TIPS Bond ETF trades at $104.65 (market cap $14.17B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: iShares TIPS Bond ETF is far larger — about 5.2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares TIPS Bond ETF for 61 Days and TransMedics Group Inc for 24 Days on average.
| TIP | TMDX | |
|---|---|---|
Market Cap | $14.17B | $2.74B |
Volume | 1,780,688 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $112.20 | $150.42 |
52-Week Low | $103.98 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TIP trades at $104.24 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution while oscillators remain neutral. The ETF faces headwinds from rising bond yields and inflationary pressures affecting fixed income markets. Recent institutional activity shows Envestnet Asset Management increased its stake by 3.5% in the latest quarter.
The outlook remains challenging amid persistent bond market volatility and rising interest rates. Investment opportunity exists for inflation-protected exposure, though risks include continued yield increases and geopolitical tensions driving oil prices higher. Current technical weakness suggests cautious positioning may be warranted until market conditions stabilize.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
